CTLA4 and neoplasm: For example, differences in the immune checkpoint inhibitors evaluated (e.g., anti–PD-1 monotherapy and combination of anti–PD-1 and anti–CTLA-4 therapy), particularly when comparing studies across tumor types, complicate the ability to generalize the results of these studies.